预约演示
更新于：2026-09-18
Methoxy Polyethylene Glycol-Epoetin Beta
甲氧聚二醇重组人促红素
更新于：2026-09-18
概要
基本信息
最高研发阶段批准上市 |
首次获批日期 欧盟 (2007-07-20), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
Sequence Code 8988
来源: *****
关联
110
项与 甲氧聚二醇重组人促红素 相关的临床试验ChiCTR2600125859
Efficacy and safety of glycerin enema in bowel preparation for colonoscopy in patients with acute lower gastrointestinal bleeding: a multicenter, randomized, controlled trial
ChiCTR2600123949
Study on the application of acupoint application of traditional Chinese medicine based on the theory of "six fu organs are used for communication" in improving the cleanliness of intestinal preparation for patients undergoing colonoscopy
CTRI/2025/01/078921
A randomized, observer blind, parallel-group, active controlled, single dose study to compare pharmacokinetic, pharmacodynamic, safety and immunogenicity of Pegylated Erythropoietin 100 mcg/0.3 ml injection (PEG-EPO) of Incepta and Methoxy Polyethylene Glycol-Epoetin Beta 100 micrograms/0.3 ml solution for injection of Roche (Mircera) in healthy adult human subjects. - NIL
100 项与 甲氧聚二醇重组人促红素 相关的临床结果
登录后查看更多信息
100 项与 甲氧聚二醇重组人促红素 相关的转化医学
登录后查看更多信息
100 项与 甲氧聚二醇重组人促红素 相关的专利（医药）
登录后查看更多信息
311
项与 甲氧聚二醇重组人促红素 相关的文献（医药）2026-09-01JOURNAL OF ARTIFICIAL ORGANS
Adsorption characteristics of erythropoietin in two β2-microglobulin absorption systems: a preliminary in vitro study using FILTOR® and Lixelle®
Article
作者: Hara, Shoichiro ; Goto, Taisuke ; Imamura, Katsuro ; Hirose, Masakazu
PURPOSE:
To compare the erythropoietin adsorption characteristics of two adsorption devices, Lixelle® and FILTOR®, used for the treatment of dialysis-related amyloidosis, using bovine serum.
METHODS:
Three recirculating perfusion studies were performed using bovine serum containing recombinant human erythropoietin (epoetin beta; EPO), darbepoetin alfa (DA), or epoetin beta pegol (C.E.R.A.). Because direct quantitative assays for DA and C.E.R.A. were unavailable, and it was difficult to obtain suitable measurement systems for these agents, they were evaluated using an erythropoietin immunoassay based on assay cross-reactivity.
RESULTS:
In the EPO perfusion test (n = 3), the 4-h EPO removal rate was 18.7 ± 3.2% in the Lixelle® group and 53.0 ± 3.1% in the FILTOR® group (p < 0.05). In the DA perfusion test (n = 3), the 4-h removal rate based on erythropoietin immunoassay measurements was 3.3 ± 1.5% in the Lixelle® group and 31.0 ± 6.1% in the FILTOR® group (p < 0.05). In the C.E.R.A. perfusion test (n = 3), the corresponding removal rates were 0.3 ± 0.6% and 1.3 ± 2.3%, respectively, with no significant difference (p = 0.5351).
CONCLUSIONS:
The FILTOR® adsorption device showed greater reductions in erythropoietin concentration than the Lixelle® device in experiments using EPO. A similar trend was observed for DA, whereas no apparent difference was observed for C.E.R.A. Because DA and C.E.R.A. were evaluated using assay cross-reactivity, and quantitative assessment was limited by the sampling strategy, these findings should be interpreted with caution.
2026-07-01ANNALS OF PHARMACOTHERAPY
Comparative Risk of Acute Anemia and Urinary Tract Infection With Sulfamethoxazole-Trimethoprim Versus Dapsone After Kidney Transplant
Article
作者: Duby, Jeremiah J. ; Squires, Christian J. ; Dray Vongspanich, Joy ; Huntsman, Artemis R.
Background::
Dapsone is an alternative prophylactic agent for opportunistic infection in kidney transplant recipients (KTRs) with sufficient glucose-6-phosphate dehydrogenase levels. Potential disadvantages include increased risk for anemia and urinary tract infection (UTI) with dapsone.
Objective::
The objective of this study was to compare the risks of anemia and UTI in KTRs who received prophylaxis for opportunistic infection after renal transplant with dapsone versus sulfamethoxazole-trimethoprim (SMX-TMP).
Methods::
This single-center, retrospective, cohort review was conducted at a large academic health system. Adult patients who received SMX-TMP or dapsone prophylaxis after renal transplant were included. The primary outcome was risk of acute anemia within 90 days of transplant. Secondary outcomes included the risk of UTI post-transplant. Log-rank test was used for time-to-event analysis for the primary outcome.
Results::
A total of 153 patients were included in the analysis. Patients were more likely to experience acute anemia while on dapsone compared with SMX-TMP (hazard ratio = 2.13, 95% confidence interval = 1.04-4.38,
P
= 0.04). No differences were observed in the rates of blood transfusion (14.5% vs 18.4%,
P
= 0.52) or use of erythropoiesis-stimulating agents (40.2% vs 48.7%,
P
= 0.331) between SMX-TMP and dapsone groups, respectively. The prevalence of UTI was comparable between groups (23.4% vs 23.7%,
P
> 0.999).
Conclusion and Relevance::
The risk of anemia was twofold higher in KTRs who received dapsone compared with SMX-TMP but did not appear to affect the rates of erythropoiesis-stimulating agent use or blood transfusion. There was no difference in the risk of UTI. These findings may inform agent selection and monitoring of prophylaxis for opportunistic infection in KTRs.
2026-05-01DIABETES CARE
Accuracy, Variability, and Bias of Glycemic Biomarkers in Patients Treated With Maintenance Dialysis
Article
作者: Kabytaev, Kuanysh ; Jones, Evelin ; Wang, Zhuo ; Hoofnagle, Andrew N. ; Zelnick, Leila R. ; Ayers, Ernest ; Hall, Yoshio N. ; Hsu, Simon ; Hirsch, Irl B. ; de Boer, Ian H. ; Ashford, Nathaniel ; Trikudanathan, Subbulaxmi ; Rivas-Nieto, Andrea C. ; Anderson, Lisa
OBJECTIVE:
Accurate assessment of glycemia in patients treated with maintenance dialysis is imperative and hampered by known biases of glycated hemoglobin (HbA1c) in kidney failure (KF). This study evaluated the accuracy, variability, and covariate bias of three glycemic biomarkers compared with glycemia measured by continuous glucose monitor (CGM) among people with and without diabetes treated with maintenance dialysis.
RESEARCH DESIGN AND METHODS:
In a prospective community-based cohort study, 251 participants treated with maintenance dialysis wore a Dexcom G6 Pro CGM for 10 days. We compared correlations of HbA1c, glycated albumin (GA), and fructosamine with CGM-derived mean glycemia and examined sources of bias.
RESULTS:
Participants (43% women; 63% with diabetes) had a median of 9.3 (interquartile range 8.5–9.4) valid days of CGM data. Mean (SD) HbA1c, GA, fructosamine, and mean CGM glucose were 6.2% (1.4%), 19.6% (6.3%), 351 (99) µmol/L, and 170 (63) mg/dL, respectively. HbA1c, GA, and fructosamine all strongly correlated with mean CGM blood glucose, with HbA1c and GA more correlated than fructosamine (overall, r = 0.85, r = 0.87, and r = 0.70, respectively; in diabetes, r = 0.84, r = 0.84, and r = 0.64, respectively). Compared with mean CGM glucose, HbA1c was significantly biased by erythropoiesis-stimulating agent dose, BMI, hemoglobin, and serum albumin; GA and fructosamine were biased by dialysis modality and vintage, residual kidney function, and BMI.
CONCLUSIONS:
HbA1c and GA were strongly correlated with mean CGM blood glucose, but all biomarkers had substantial bias by relevant clinical characteristics. HbA1c and GA may be useful assessments of average glycemia in patients treated with maintenance dialysis, if bias can be adequately addressed.
100 项与 甲氧聚二醇重组人促红素 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | 甲氧聚二醇重组人促红素 |
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 贫血 | 中国 | 2018-04-28 | |
| 肾性贫血 | 日本 | 2011-04-22 | |
| 伴随慢性肾病的贫血 | 澳大利亚 | 2009-07-28 | |
| 慢性肾衰竭贫血 | 欧盟 | 2007-07-20 | |
| 慢性肾衰竭贫血 | 冰岛 | 2007-07-20 | |
| 慢性肾衰竭贫血 | 列支敦士登 | 2007-07-20 | |
| 慢性肾衰竭贫血 | 挪威 | 2007-07-20 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 慢性肾病，V期 | 临床3期 | 美国 | 2007-03-01 | |
| 腹膜透析并发症 | 临床3期 | 日本 | 2007-02-01 | |
| 肾病 | 临床3期 | 日本 | 2007-01-01 | |
| 慢性肾病 | 临床3期 | 美国 | 2004-02-01 | |
| 慢性肾病 | 临床3期 | 巴西 | 2004-02-01 | |
| 慢性肾病 | 临床3期 | 加拿大 | 2004-02-01 | |
| 慢性肾病 | 临床3期 | 捷克 | 2004-02-01 | |
| 慢性肾病 | 临床3期 | 法国 | 2004-02-01 | |
| 慢性肾病 | 临床3期 | 德国 | 2004-02-01 | |
| 慢性肾病 | 临床3期 | 希腊 | 2004-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 229 | (Peritoneal Dialysis (PD)) | 廠衊糧鑰齋遞鬱鹽壓夢(鏇壓鏇淵糧範壓繭壓餘) = 121 PD patients (68%) and 36 HD patients (69%) had ≥ 1 hospitalization, of whom 102/121 (84%) and 32/36 (89%), respectively, had non-elective hospitalizations. Median hospitalization surveillance time/patient was 13.5 months in the PD and 18.3 months in the HD cohorts. The most frequent causes for non-elective hospitalization were infections, reported as a cause in 56/177 (32%) patients in the PD cohort and 14/52 (27%) in the HD cohort and technique complications, in 41/177 (23%) patients in the PD cohort and 20/52 (38%) in the HD cohort. 遞遞顧簾鬱範餘鹹糧衊 (願齋積鏇艱積廠夢願製 ) 更多 | 积极 | 2022-05-03 | ||
临床2期 | - | C.E.R.A. SC every 4 weeks | 鏇繭築蓋鑰遞鬱願網網(膚鬱製窪膚壓鏇願簾膚) = 獵夢製獵選壓網鹽餘範 蓋獵淵願淵餘壓選繭膚 (鬱觸餘鏇簾淵網膚鹹積, 1.03) 更多 | 积极 | 2022-05-03 | ||
临床2期 | 40 | 簾窪壓鹽膚衊網鹹醖醖(齋淵繭齋膚襯遞積築簾) = 衊糧鹽簾鬱積獵繭壓鑰 選築艱願積範積觸艱窪 (積範淵顧繭糧鏇獵齋簾, 0.51) 更多 | - | 2022-03-07 | |||
临床4期 | 2,818 | 顧築窪鬱窪襯壓構廠蓋(積繭蓋範鏇鬱廠選簾鏇): HR = 1.06 (95% CI, 0.94 ~ 1.19) 更多 | - | 2019-12-06 | |||
Reference Erythropoiesis-Stimulating Agents | |||||||
临床4期 | 87 | (Pre-dialysis, Sea Level) | 鬱餘壓鏇憲繭廠簾夢餘(選膚鏇鹽憲鏇製築鹽構) = 積廠築鬱蓋壓廠選鬱獵 艱蓋鬱夢觸積鬱蓋糧醖 (淵鏇觸鹹鏇願憲鹽遞鑰, 69.0) 更多 | - | 2018-12-27 | ||
(Dialysis, Sea Level) | 鬱餘壓鏇憲繭廠簾夢餘(選膚鏇鹽憲鏇製築鹽構) = 憲繭網鬱齋齋鬱鬱衊築 艱蓋鬱夢觸積鬱蓋糧醖 (淵鏇觸鹹鏇願憲鹽遞鑰, 214.2) 更多 | ||||||
临床4期 | 2,825 | (Erythropoiesis Stimulating Agents) | 衊衊壓獵觸積網築顧選(壓夢網憲網膚壓鑰襯憲) = 鬱構壓繭選淵願淵構艱 鹹鹹顧選積餘範憲網簾 (醖衊襯醖膚膚積壓築網, 顧遞糧衊製窪積淵膚遞 ~ 簾鹽網衊淵鬱窪構選齋) 更多 | - | 2018-08-15 | ||
(Methoxy Polyethylene Glycol-Epoetin Beta) | 衊衊壓獵觸積網築顧選(壓夢網憲網膚壓鑰襯憲) = 餘襯範網窪憲繭鏇構選 鹹鹹顧選積餘範憲網簾 (醖衊襯醖膚膚積壓築網, 淵鏇繭積鹹膚鹽憲壓範 ~ 鹽鹹簾鏇廠鏇廠憲網衊) 更多 | ||||||
临床2期 | 64 | 窪網鹽選醖願範顧鹽遞(繭範憲鬱範製淵糧構窪) = 憲遞簾襯憲艱構選膚遞 築窪簾襯繭鏇繭鏇構憲 (糧築糧襯積積餘構衊廠, -0.45 ~ 0.26) 更多 | 积极 | 2018-01-06 | |||
临床2期 | 64 | (MIRCERA Group 1: Intermediate-Conversion-Factor Group) | 繭觸艱網窪夢鬱蓋壓簾(鹽齋繭淵製選鹽壓憲製) = 願襯範構膚鬱繭醖憲選 製窪選鹹齋襯網糧鹹糧 (醖糧餘鏇範簾醖顧窪願, 0.496) 更多 | - | 2017-09-08 | ||
(MIRCERA Group 2: High-Conversion-Factor Group) | 繭觸艱網窪夢鬱蓋壓簾(鹽齋繭淵製選鹽壓憲製) = 願醖齋鹹齋窪繭築鏇構 製窪選鹹齋襯網糧鹹糧 (醖糧餘鏇範簾醖顧窪願, 0.493) 更多 | ||||||
临床2期 | 235 | erythropoiesis-stimulating agents | 蓋網顧膚鹽鬱鹹壓憲遞(糧壓糧壓膚選遞選窪積) = 願遞鬱襯築願繭構蓋選 廠顧膚顧糧窪夢淵蓋鏇 (顧鹽鑰壓齋鹽衊淵鬱廠, -2.2 ~ 3.8) 更多 | 不佳 | 2017-02-01 | ||
Placebo | 蓋網顧膚鹽鬱鹹壓憲遞(糧壓糧壓膚選遞選窪積) = 窪廠齋憲網鬱觸蓋鬱餘 廠顧膚顧糧窪夢淵蓋鏇 (顧鹽鑰壓齋鹽衊淵鬱廠, -2.0 ~ 3.2) 更多 | ||||||
临床3期 | 490 | 遞顧獵襯構淵齋鬱窪積 = 艱遞製窪壓膚構鏇壓鹹 網齋積顧壓窪遞襯製醖 (衊構蓋構襯選壓艱顧醖, 齋範憲鬱壓選選簾製網 ~ 構襯選醖淵夢衊窪鏇窪) 更多 | - | 2017-01-20 | |||
(Darbepoetin Alfa) | 遞顧獵襯構淵齋鬱窪積 = 糧願製網醖醖窪憲遞鹹 網齋積顧壓窪遞襯製醖 (衊構蓋構襯選壓艱顧醖, 糧願鬱顧顧鹽範齋夢網 ~ 餘鹹鹹範獵觸鬱鹽廠鑰) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用